Pathway to Cures (P2C), the venture philanthropy fund of the National Bleeding Disorders Foundation (NBDF), is pleased to announce the appointment of Michael Recht, MD, PhD, MBA, as chief medical and scientific advisor.
Building on his tenure as NBDF’s chief medical and scientific officer, Dr. Recht will lead P2C’s engagement with emerging biotech companies to identify and evaluate breakthrough technologies with the potential to serve as curative therapies for people with blood and bleeding disorders. He also continues his leadership role as chair of P2C’s Scientific Advisory Group.
"Transitioning from my role as chief medical and scientific officer at NBDF to this advisory position at Pathway to Cures allows me to apply years of strategic oversight and clinical leadership directly to the frontier of medical innovation," said Dr. Recht. "By combining the scientific rigor I championed at NBDF with P2C’s venture philanthropy model, we are uniquely positioned to bridge the gap between promising research and life-changing cures. Crucially, as we collaborate with emerging biotechnology companies, the input of lived experience experts will remain a cornerstone of our approach. By integrating their real-world experience into our investments, we ensure health access and strategic innovation remains at the center of our goals and that these innovations reach and benefit every member of the blood and bleeding disorders community."
“Dr. Recht’s uniquely integrated viewpoint, combining scientific knowledge with clinical experience, is invaluable to developing meaningful outcomes for our community,” said Teri Willey, managing director and officer of Pathway to Cures. Importantly, it puts us in a position to encourage and advise innovators who have the means to find curative therapies for rare diseases, to include inheritable bleeding areas as part of their research and development portfolio.”
About Dr. Michael Recht
Dr. Recht is an internationally respected leader in pediatric hematology and a professor of clinical pediatrics at the Yale School of Medicine where he sees infants, children, adolescents, and young adults with inheritable blood and bleeding disorders. In addition, Dr. Recht is the primary investigator of multiple investigator-initiated as well as industry-sponsored trials at the university. Over the course of his career, Dr. Recht has held leadership roles including Chief Medical and Scientific Officer at the National Bleeding Disorders Foundation, Chief Science Officer for the American Thrombosis and Hemostasis Network, and Director of the Hemophilia Center at Oregon Health & Science University and Mountain States Hemophilia Network. He has served as lead investigator on more than 110 clinical trials, most recently focused on gene therapy for hemophilia.
About Pathway to Cures (P2C)
Pathway to Cures (P2C) is the National Bleeding Disorders Foundation’s venture philanthropy fund created specifically to accelerate the development of cures and therapies across all inheritable blood and bleeding disorders.
As a flexible partner working collaboratively with other organizations, P2C makes investments in innovative therapies, and technologies, leveraging the deep resources and scientific community relationships of the National Bleeding Disorders Foundation (NBDF). By reinvesting proceeds from investments back into the Fund, P2C will amplify our impact by supporting the progress of promising companies and building a deep and diverse portfolio of investments that further our mission.
